
Clinical Trials
Clinical trials offer patients the opportunity to become involved in treatments that may well become tomorrow’s standard of care.
Breakthrough Trial
Study of CF33-hNIS (VAXINIA), Oncolytic Virus, as Monotherapy or in Combination with Pembrolizumab
with Metastatic or Advanced Solid Tumors (MAST): One confirmed Complete Response Durable for more than 1.5 years
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
Evaluating the New Cholangiocarcinoma Vaccine Trial: A Patient-Centric Analysis”
An in-depth analysis of a cholangiocarcinoma vaccine trial, designed to empower patients with balanced insights into this experimental treatment.
Meet GEM/CIS/DURVA: A Formidable Trio in the Fight Against Cancer
Discover how GEM/CIS/DURVA works to fight cholangiocarcinoma more effectively
Bile Gone Bad: The Rising Incidence of Bile Duct Cancer – The Hidden Dangers within Bile Composition
Is your diet turning your bile toxic? Learn about the hidden cancer risks and how to protect your health.
We are currently awaiting the IDH1 Drug Tibsivo to be included on the PBS
Search for Trials and Studies
Genomic Focus
Genomic Focus, offer a more real-time resource to match patients’ genetic mutations with clinical trials worldwide. This free service helps you and your medical team find personalised treatment options, enhancing knowledge access to targeted therapies. Genomic Focus is dedicated to empowering patients, operating independently without profit partnerships, focusing solely on enhancing patient care.
Australian Search
Australian Cancer Trials; australiancancertrials.gov.au/
USA Search
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.
- Search Cholangiocarcinoma
- Search Bile Duct Cancer
- Search Solid Tumor
- CCF USA Clinical Trials Explained
- CCF USA Understand Trial Response
Learn More About Trials
Learn More About Treatments
Questions – Answers – Links: Understanding Clinical Trials
Please note that the clinical trials mentioned are not the only clinical trials available for cholangiocarcinoma patients, the following clinical trials were submitted by the organisations conducting the trial. Please visit Australian Cancer Trials or for a global reference visit clinicaltrials.gov for a more comprehensive list.
Exploring Options Beyond Standard Treatment: It’s important to know that the clinical trials we mention are just a part of the wider spectrum available for cholangiocarcinoma patients. While many new tests and treatments are in development, they may not be publicly available or considered first-line options yet. These are often explored in clinical trials, which can offer access to potential future standard treatments. For a more comprehensive list of trials, visit Australian Cancer Trials for local options, or clinicaltrials.gov for global trials.
Clinical Trials: An Opportunity for New Treatments: In Australia, clinical trial options for cholangiocarcinoma may seem limited, but it’s worthwhile to research all available opportunities. Participation in clinical trials requires specific biomarkers related to your cancer, making it essential to get a biopsy. Initially, a simple and quick IHC test can be done, followed by a more comprehensive molecular (Genomic) profile if needed.
Advocating for Your Health: Don’t assume your surgeon or oncologist will automatically conduct an IHC test or other specific tests. It’s crucial to proactively discuss and request tests like PD-L1, MSI Results, CTLA-4, and HER2, as they can influence your treatment options, including eligibility for certain clinical trials.
Guidance, Not Prescription: The Cholangiocarcinoma Foundation Australia aims to empower you with information to better understand your health condition and current medical approaches. However, this is not a substitute for professional medical advice. Always consult your physician or a qualified healthcare provider for personalized guidance.